Unknown PHASE2 INTERVENTIONAL 2-arm NCT05162625

Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial

Sponsor: University of Campinas, Brazil

Conditions Endophthalmitis Moxifloxacin Open Globe Injury Post-Traumatic Endophthalmitis

Interventions Ciprofloxacin 400 MG/200 ML Intravenous Solution [CIPRO IV] Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution

Updated 4 times since 2022 Last updated: Dec 6, 2021 Started: Dec 10, 2021 Primary completion: Dec 10, 2022 Completion: Dec 10, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Endophthalmitis and Moxifloxacin and is currently ongoing. University of Campinas, Brazil leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2022 — Jan 2024 [monthly]

Recruiting PHASE2

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Campinas, Brazil

Data source: University of Campinas, Brazil

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Campinas, Brazil